one liner about RX5 is not really reassuring. they haven't told the market that it needs (and apparently is already undergoing?) ethics re-approval is a dog move by the company given how long ethics approvals take. RX5 is the company's only drug with a commercial partnership and they are stuck in a p3 trial that is going to be at least 1year overdue. clinical revenues of $1m/qtr isn't going to cover operating costs.
Ann: Company Overview and Strategic Update, page-12
Add EMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.29M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 361400 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 25555 | 1 |
View Market Depth
| Last trade - 10.02am 04/11/2024 (20 minute delay) ? |
| EMD (ASX) Chart |
Day chart unavailable